for the PCORnet Bariatric Study Collaborative* Background: There has been a dramatic shift in use of bariatric procedures, but little is known about their long-term comparative effectiveness.
evidence-based and patient-centered health care. The PBS aims to compare the safety and effectiveness of the most common bariatric procedures in the United States (16, 17) by examining electronic health record data from 11 geographically diverse PCORnet Clinical Data Research Networks (CDRNs) (18) .
In this article, we present findings on the comparative effectiveness of SG, RYGB, and AGB for weight loss among adults at 1, 3, and 5 years after surgery. We hypothesized that the procedures would lead to significantly different weight loss trajectories over 5 years. In addition, we leveraged the large sample size enabled by PCORnet to explore the effects of bariatric procedures in clinical subpopulations. These results could help patients, providers, and payers better understand how different bariatric procedures affect health.
METHODS

Study Setting and Population
The PBS cohort and protocol were previously described (16) . The study was approved by the Institutional Review Board (IRB) of Kaiser Permanente Washington Health Research Institute (lead site) and was approved or determined to be exempt from review by participating sites through individual IRB review or reliance agreements. The PBS is guided by a stakeholder advisory group (comprising patients, advocacy groups, adult and pediatric surgeons, obesity medicine providers, and payers) that helped identify relevant outcomes, prioritize analyses, advise on study design, and plan for dissemination of findings.
We identified patients who had a primary bariatric procedure at health systems affiliated with participating CDRNs (Appendix Table 1 , available at Annals.org) from 1 January 2005 through 30 September 2015. PCORnet uses a common data model to facilitate queries of standardized data (18) . The PBS team collaborated with the PCORnet Coordinating Center to develop a bariatric case definition and query program. The cohort was identified using codes from the International Classification of Diseases, Ninth Revision (ICD-9); Current Procedural Terminology (CPT-4); and the Healthcare Common Procedure Coding System (Appendix Tables 2 and 3, available at Annals.org), which were extracted from the PCORnet common data model at each site.
Bariatric procedures were identified from more than 100 million patient records in 41 health systems from the 11 CDRNs. The inclusion and exclusion criteria are shown in Figure 1 . For each patient, the first observed bariatric procedure was considered the index procedure; these had to occur in inpatient or ambulatory care encounters. We then excluded patients who were younger than 20 years or aged 80 years or older at the index procedure (n = 1809); those with multiple conflicting bariatric procedure codes on the same day (n = 1113); those with any revisional bariatric procedure code (n = 4576), gastrointestinal cancer diagnosis code (n = 4027), or fundoplasty (n = 119) in the year before the index procedure; those with an emergency department encounter on the day of the index procedure (n = 485); and those with no body mass index (BMI) data (n = 12 510) or no BMI of 35 kg/m 2 or greater (n = 1918) in the year before the procedure. We then excluded 18 583 patients who did not have a BMI measurement at 1, 3, or 5 years after surgery, resulting in a final sample of 46 510 adults with baseline and follow-up BMI measurements.
Data Extraction
We used SAS queries developed by the PCORnet Coordinating Center to extract information on eligible patients from participating sites, including site identifier; year of surgery; age at the index procedure; sex; race/ethnicity; deidentified dates of all encounters; all measures of height, weight, BMI, and blood pressure; all repeated or revisional bariatric procedures; presence of relevant comorbidities (anxiety, deep venous thrombosis, depression, eating disorder, type 2 diabetes, dyslipidemia, gastroesophageal reflux disease, hypertension, infertility, kidney disease, nonalcoholic fatty liver disease, obstructive sleep apnea, lower-extremity osteoarthritis, polycystic ovarian syndrome, psychosis, 
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Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss ORIGINAL RESEARCH pulmonary embolism, smoking, or substance use disorder); and all diagnoses and procedures related to pregnancy. We used information from the year before surgery to calculate the Charlson-Elixhauser comorbidity index score for each patient (19) . The Charlson-Elixhauser index was developed to predict mortality in older adults, but we used it to help address potential confounding because patients with higher risk for death might be offered a lower-risk procedure. Diagnoses were identified through ICD-9-CM and Systematized Nomenclature of Medicine codes (available on request). Additional details on variable construction are provided in the Statistical Appendix section of the Supplement (available at Annals.org).
Outcomes
Our primary outcome was percent total weight loss (TWL) at 1, 3, and 5 years, calculated as follows: (weight in kilograms at each time point Ϫ weight in kilograms at surgery)/weight in kilograms at surgery × 100 (20) . We used pairwise comparisons of percent TWL between procedures (RYGB vs. SG, SG vs. AGB, and RYGB vs. AGB) among patients with at least 1 weight measurement at 1 year (6 to 18 months), 3 years (30 to 42 months), and 5 years (54 to 66 months) after surgery. Follow-up for weight measurements began at the index procedure date and ceased at the end of the study period (30 September 2015) or when the patient switched to a different bariatric procedure. Because pregnancy affects body weight, we ignored anthropometric measurements during pregnancy, defined as the 9 months before and the 3 months after any code indicating full-term delivery, preterm delivery, miscarriage, or abortion. Data were cleaned to remove biologically implausible values for height (<4 or ≥8 ft), weight (<70 or ≥700 lb), and BMI (<15 or ≥90 kg/m 2 ) (21). Secondary analyses examined the proportion of patients achieving TWL greater than 5%, 10%, 20%, and 30% at each time point.
We also examined 30-day rates of major adverse events, defined as any death, reoperation, percutaneous or endoscopic intervention, venous thromboembolism, or failure to be discharged from the hospital within 30 days (22, 23) , among 65 093 patients who had complete information at baseline. Longer-term data on adverse events were not available.
Statistical Analysis
Weight Loss Outcomes
Mean adjusted weight at 1, 3, and 5 years with each procedure was estimated using a linear mixedeffects (random-effects) model framework (24) . For patients included in each pairwise comparison at each time point, all available postsurgery weight measures were used. Each model estimated a mean populationlevel time-varying curve for the trend in weight from the time of surgery to the end of the study and included random-effects terms for patient (intercept) and follow-up time (slope). For clinical relevance in presentation, we transformed mean adjusted weight to mean percent TWL and mean weight change, but all inferences were made on the mean weight estimates (including P values) and 95% CIs were transformed from those for mean weight. Additional details are provided in the Statistical Appendix section of the Supplement.
Confounding
To control for potential confounding variables, a propensity score model was constructed for each pairwise analysis and time point cohort. The propensity score estimated the probability of having a specific bariatric procedure given baseline (presurgery) covariates. In each cohort, variables were selected and parameters were estimated simultaneously using maximum penalized likelihood estimation and the LASSO (least absolute shrinkage and selection operator) method (see the Statistical Appendix section of the Supplement for details) (25) . In addition to adjusting for deciles of predicted propensity score, we included main effects for weight, sex, age, and all other baseline covariates in the outcome model ( Table 1) .
Subgroup Analyses
We examined potential variability in treatment effects across baseline patient characteristics (aged ≥65 or <65 years, sex, race/ethnicity, presence or absence of diabetes, and BMI ≥50 or <50 kg/m 2 ) by including an interaction term between procedure type and each characteristic of interest in the random-effects model framework. Subgroups were chosen on the basis of consensus among study stakeholders, including patients and providers. 
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Sensitivity Analyses
To assess the effects of dropout and missing baseline data on our results, we compared the results of our primary analysis with those from a simple covariateadjusted model (no propensity scores) run on a single data set that included all longitudinal data among patients with at least 1 postsurgery measurement (n = 56 156) and excluded the race, ethnicity, and blood pressure variables, which were the primary sources of missing baseline data. To address concerns about lack of overlap of the propensity scores, we compared our primary results with those we obtained after trimming the propensity scores for each pairwise analysis and refitting the propensity score and outcome models (further details are provided in the Statistical Appendix section of the Supplement). In addition, we examined how the results of each analysis changed if we removed follow-up censoring due to switching to a different procedure. Finally, because the SG technique evolved rapidly during the study period (26, 27) , we examined whether 1-year weight loss for SG patients differed by year of surgery.
Role of the Funding Source
The Patient-Centered Outcomes Research Institute had no role in the design or conduct of the study or the reporting of the results.
RESULTS
Characteristics of the PBS Cohort
The PBS analytic sample included 46 510 patients (24 982 RYGB patients, 18 961 SG patients, and 2567 AGB patients) ( Table 1 ) with at least 1 weight measurement at 1, 3, or 5 years after surgery. The total numbers of patients with at least 1 BMI measurement at 1, 3, and 5 years were 44 978, 20 783, and 7159, respectively, representing 84%, 68%, and 69% of the 53 351, 30 521, and 10 442 patients who were eligible to be observed at those time points (Table 2 of the Supplement). Fiveyear follow-up rates differed by procedure, with 86% of SG patients, 67% of RYGB patients, and 55% of AGB patients having a weight measure in this period ( Table  2 of the Supplement).
Patients were predominantly white (74%); 21% were African American, and 21% were Hispanic. At baseline, RYGB patients had higher mean BMI (49.6 kg/m 2 ), were more often white (80%), and had greater prevalence of most comorbid conditions than SG or AGB patients. The frequency of procedure types differed across study years, with a sharp decrease in AGB, a sharp increase in SG, and a gradual decrease in RYGB (16) .
We compared characteristics of patients in our analytic cohort with those who were excluded due to missing BMI data at baseline and during follow-up (Table 3 of the Supplement). Those without follow-up BMI data were younger (44 vs. 46 years), were less often white (67% vs. 74%), had more recent procedures, and had fewer comorbid conditions. Baseline BMI was more often missing for AGB patients (49%) than RYGB (17%) or SG (9%) patients.
Thirty-Day Rates of Major Adverse Events
Thirty-day rates of major adverse events ( Table 4 of the Supplement) were 5.0% for RYGB patients (n = AGB = adjustable gastric banding; RYGB = Roux-en-Y gastric bypass; SG = sleeve gastrectomy; TWL = total weight loss. * TWL was calculated as follows: (weight in kilograms at 1, 3, and 5 y -weight in kilograms at baseline)/weight in kilograms at baseline × 100. A propensity score model was constructed for each pairwise analysis and time point. Age at index procedure, sex, race/ethnicity, year of index procedure, baseline body mass index, number of days from baseline weight to bariatric surgery, and baseline Charlson-Elixhauser comorbidity index score were forced into all propensity score models. Site, smoking status, inpatient hospitalizations in the year before surgery, baseline blood pressure, and comorbidities at baseline were included subject to the variable selection process. Further, to account for differing effects of confounders on propensity scores by site, interactions between site and all confounders were made available for selection. In addition to adjustment for deciles of the predicted propensity score, we included main effects for baseline weight, sex, age, and all other baseline covariates listed here in the outcome model. 
Comparative Effectiveness for Weight Loss
Patients having RYGB had the greatest percent TWL at each time point, and AGB patients had the lowest (Table 2 and Figure 2) . At 1 year, average TWL was 31.2% (CI, 31.1% to 31.3%; mean weight loss, 39.6 kg) for RYGB patients, 25.2% (CI, 25.1% to 25.4%; mean weight loss, 32.0 kg) for SG patients, and 13.7% (CI, 13.3% to 14.0%; mean weight loss, 17.3 kg) for AGB patients. Patients having RYGB lost 5.9 (CI, 5.8 to 6.1) percentage points (7.6 kg) more of their baseline weight at 1 year than SG patients and 17.7 (CI, 17.3 to 18.1) percentage points (22.5 kg) more than AGB patients. Patients having SG lost 12.0 (CI, 11.6 to 12.5) percentage points (15.3 kg) more of their baseline weight at 1 year than AGB patients ( Table 2) .
At 5 years, patients in each group had, on average, regained some weight. The AGB group regained the least (11.7% TWL at 5 years vs. 13.7% at 1 year; mean weight regained, 2.5 kg), followed by the RYGB (25.5% at 5 years vs. 31.2% at 1 year; mean weight regained, 7.2 kg) and SG (18.8% at 5 years vs. 25.2% at 1 year; mean weight regained, 8.2 kg) groups. Despite these patterns, RYGB patients still had significantly greater TWL after 5 years than SG (difference, 6.7 [CI, 5.8 to 7.7] percentage points; P < 0.001) and AGB (difference, 13.9 [CI, 12.4 to 15.4] percentage points; P < 0.001) patients, and the SG group had significantly greater TWL than the AGB group (difference, 7.3 [CI, 5.2 to 9.3] percentage points; P < 0.001). Figure 2 illustrates the rapid weight loss with all procedures. After 1.5 years, each group had a slow and steady weight regain through 5.5 years of follow-up.
Nearly all patients who had RYGB and SG achieved an estimated TWL greater than 5% at 1, 3, and 5 years ( Figure 3) . Patients having RYGB were more likely to achieve TWL greater than 10%, 20%, and 30% at all time points. Patients having AGB were less likely to achieve TWL greater than 5%, 10%, 20%, or 30% at all time points compared with RYGB and SG patients.
Weight Loss in Patient Subgroups
Patients with diabetes lost less weight than those without diabetes at all time points for all procedures ( Table 5 of the Supplement). Patients with a BMI less than 50 kg/m 2 at the time of surgery lost less weight than those with a BMI of 50 kg/m 2 or greater at all time points for RYGB and SG. This difference was seen at 1 and 3 years in AGB patients, but by 5 years there was no significant difference ( Table 6 of the Supplement). Patients aged 65 years or older at the time of surgery lost less weight than younger patients with RYGB and SG at all time points; however, there was no difference by age for AGB at any time point ( Table 7 of the Supplement). Men lost less weight with AGB than women at all time points. Men lost more weight with RYGB and SG at 1 year, but there were no differences at 3 and 5 years ( Table 8 of the Supplement). African American patients lost less weight with RYGB and SG than white patients at all time points. Hispanic patients lost less weight with RYGB than white patients at all time points. This difference was also seen with SG and AGB at 1 and 3 years, but there were no significant differences at 5 years ( Table 9 of the Supplement).
Sensitivity Analyses
Findings did not change when we removed follow-up censoring due to switching to a different bariatric procedure or when we examined whether 1-year weight loss for SG patients differed by year of surgery. Our sensitivity analysis model, which was run on a single data set that included all longitudinal data (n = 56 156), estimated lower TWL for AGB (8.1%), similar TWL for SG (18.7%), and slightly greater TWL for RYGB (26.3%) at 5 years compared with our main model estimates; other estimates were qualitatively similar ( Table  10 of the Supplement). Estimates from the trimmed propensity score sensitivity analyses were similar to those from our primary analysis (Table 11 of the Supplement), except that the 5-year comparison between SG and AGB was attenuated and no longer statistically significant, although the number of AGB patients was small (n = 41) and the 95% CI still included our primary analysis estimate.
Comparisons of results by data mart and numbers of patients by site and procedure are provided in Table  1 of the Supplement. This plot shows the estimated percentage of TWL for a patient with the average baseline covariate profile using results from our sensitivity analysis, which included all follow-up weight measurements from 56 156 patients with any postsurgery weight observations. Additional details are provided in the Methods section of the text and the Statistical Appendix section of the Supplement. Shaded areas indicate pointwise 95% CIs. AGB = adjustable gastric banding; RYGB = Roux-en-Y gastric bypass; SG = sleeve gastrectomy; TWL = total weight loss.
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DISCUSSION
In this large multicenter study, we examined the comparative effectiveness of the 3 most common bariatric procedures in the United States and demonstrated clear and clinically important differences in weight loss outcomes at 1, 3, and 5 years. Patients who had RYGB lost 5.9 percentage points more weight at 1 year and 6.7 percentage points more at 5 years than SG patients. The proportion of patients achieving 5% weight loss was similar for RYGB and SG, and the proportions losing more than 10% and especially more than 20% or 30% were much larger with RYGB than SG. These findings are compelling because recent smaller studies have suggested little or no difference in short-term weight loss between RYGB and SG (10, 11, 28 -33) .
Other studies have found that RYGB results in greater weight loss than SG at 1 to 4 years of follow-up (5-8, 34 -36) . Bariatric surgical outcomes can vary widely across surgical centers (37) , but the data presented here are probably more broadly representative of the typical experience of patients having bariatric surgery in most major surgical centers in the United States. The magnitude of the weight loss differences we observed will likely be meaningful to patients and providers as they consider treatment options for severe obesity.
When this new information is applied to clinical decision making, the expected magnitude of weight loss with each procedure needs to be tailored to the patient's specific clinical situation. The large PBS sample enabled subgroup analyses, which aimed to provide Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss ORIGINAL RESEARCH data that are relevant for individualized decisions. For example, we found that patients aged 65 years or older, those with diabetes, those with a preoperative BMI less than 50 kg/m 2 , and racial minority patients generally lost less weight with RYGB and SG than younger, nondiabetic, more severely obese, and nonHispanic white patients. However, across all of the subgroups we examined, the magnitudes of the differences in TWL were clinically small and generally less than 3%. In contrast, the differences in weight loss between RYGB and SG were larger, and we did not identify any subgroup in which SG outperformed RYGB.
The magnitude of weight loss is not the only factor that patients and providers should consider when discussing bariatric procedure options, and the shared decision-making conversation should include information on risk for adverse events (such as reoperation, death, hypoglycemia, or micronutrient deficiencies) and expected changes in comorbid conditions with each procedure (38) . We found that RYGB patients had a higher 30-day rate of major adverse events (5.0%) than SG (2.6%) or AGB (2.9%) patients. To better inform these discussions, future studies should examine longer-term differences in safety outcomes across procedures.
The PBS demonstrates that PCORnet is a valuable new resource for rapidly conducting patient-centered comparative effectiveness research. Its infrastructure enabled standardization of health record data across diverse health systems and analysis of a sufficiently large cohort to identify differences in outcomes across clinically relevant patient subgroups. The engagement of stakeholders throughout the PCORnet research process may also increase the likelihood that the findings are relevant to the decision-making process as patients and providers contemplate the best weight management option (39) .
This study has several limitations. First, patients were not randomly assigned, so there was risk for unobserved confounding that may have persisted despite covariate and propensity score adjustment in our pairwise comparisons. Second, a sizable proportion of our cohort was missing BMI data in the electronic health record at baseline or during follow-up, and rates of missingness at baseline and 5 years varied across procedures. This may have introduced bias, although the magnitude and direction of that bias are uncertain. Third, weight data were not systematically collected as part of a prospective data collection effort, as in the Longitudinal Assessment of Bariatric Surgery (40) , so weights at specific time points were model-estimated predictions. Fourth, comorbid conditions were assessed and Charlson-Elixhauser scores were calculated using ICD-9 diagnosis codes, which may underestimate prevalence of comorbidities (such as osteoarthritis), can be inaccurately coded, and do not account for disease severity. Fifth, comparing the effect of bariatric procedures on obesity-related chronic conditions was beyond the scope of this work. Sixth, because this study used deidentified data, we were only able to determine the timing of procedures by year, which prevented us from identifying patients who had missing follow-up data due to administrative censoring. Seventh, we were unable to examine heterogeneity of treatment effects by site because of resource constraints. Finally, the AGB procedure may be underrepresented in this cohort because PCORnet does not include small ambulatory surgical centers.
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